Showing results (631-640 of 651) with videos related to
Sort By:
Pageof 66
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance LeukemiaChristoph Röllig, Björn Steffen, Christoph Schliemann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 TrialJia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.American Journal of Hematology|January 6, 2026
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction TherapyStefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, et al.Cell Stem Cell|May 6, 2022
Antigen presentation safeguards the integrity of the hematopoietic stem cell poolPablo Hernández-Malmierca, Dominik Vonficht, Alexandra Schnell, et al.Frontiers in Medicine|November 3, 2025
COVID-19 convalescent plasma for B-cell depleted patients: a systematic review and individual patient data meta-analysisSolomiia Zaremba, Daniele Focosi, Wyatt W Pruter, et al.The Lancet. Oncology|November 10, 2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Hubert Serve, Andreas Hüttmann, et al.Blood Advances|November 18, 2021
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter studyJan M Middeke, Klaus H Metzeler, Christoph Röllig, et al.Haematologica|May 28, 2021
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative studySabine Kayser, Richard F Schlenk, Delphine Lebon, et al.Blood|November 2, 2022
Germ line DDX41 mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, et al.Pageof 66